Brought to you by 
Tesaro gets rolapitant rights from Opko Health
27 Oct 2017
Executive Summary
Opko Health Inc. (drugs, diagnostics, and devices) has granted cancer company Tasaro Inc. exclusive worldwide rights to develop, manufacture, and market rolapitant and a related compound, both for chemotherapy induced nausea and vomiting (CINV).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tesaro gets rolapitant rights from Opko Health
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice